Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Chighizola, Cecilia Beatrice ^a,b   Ubiali, Tania ^b,c   Meroni, Pier Luigi ^a,b,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; B LYMPHOCYTE ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; DABIGATRAN; DEFIBROTIDE; ECULIZUMAB; FONDAPARINUX; HEPARIN DERIVATIVE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PROTEIN DISULFIDE ISOMERASE; RAPAMYCIN; RITUXIMAB; RIVAROXABAN; VITAMIN D;

ANTICOAGULANT THERAPY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BLEEDING; CARDIOVASCULAR RISK; CATASTROPIC ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CARRIER; DISEASE CONTROL; DRUG EFFICACY; HUMAN; IMMUNOASSAY; LOW DRUG DOSE; MORBIDITY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY ANTIPHOSPHOLIPID SYNDROME; REVIEW; RISK ASSESSMENT; THROMBOSIS; THROMBOTIC ANTIPHOSPHOLIPID SYNDROME; TREATMENT DURATION; VASCULAR DISEASE; VEIN THROMBOSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE MANAGEMENT; IMMUNOLOGY; METABOLISM; RISK;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; RISK; THROMBOSIS;

EID: 84929650173     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/951424     Document Type: Review

References (129)

1. S. Miyakis, M. D. Lockshin, T. Atsumi et al., "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)," Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295-306, 2006.
2. R. Cervera, M. A. Khamashta, Y. Shoenfeld et al., "Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients," Annals of the Rheumatic Diseases, vol. 68, no. 9, pp. 1428-1432, 2009.
3. P. L. Meroni, C. B. Chighizola, F. Rovelli, and M. Gerosa, "Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers," Arthritis Research and Therapy, vol. 16, no. 2, article 209, 2014.
4. R. Cervera, J.-C. Piette, J. Font et al., "Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients," Arthritis and Rheumatism, vol. 46, no. 4, pp. 1019-1027, 2002.
5. C. B. Chighizola, M. Gerosa, and P. L. Meroni, "New tests to detect antiphospholipid antibodies: anti-domain i beta-2-glycoprotein-I antibodies," Current Rheumatology Reports, vol. 16, no. 2, pp. 402-409, 2014.
6. P. L. Meroni, M. O. Borghi, E. Raschi, and F. Tedesco, "Pathogenesis of antiphospholipid syndrome: understanding the antibodies," Nature Reviews Rheumatology, vol. 7, no. 6, pp. 330-339, 2011.
7. G. Canaud, F. Bienaimé, F. Tabarin et al., "Inhibition of the mTORC pathway in the Antiphospholipid syndrome," The New England Journal of Medicine, vol. 371, no. 4, pp. 303-312, 2014.
8. L. Andreoli, C. B. Chighizola, A. Banzato, G. J. Pons-Estel, G. R. de Jesus, and D. Erkan, "Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature," Arthritis Care & Research, vol. 65, no. 11, pp. 1869-1873, 2013.
9. C. B. Chighizola, L. Andreoli, A. Banzato et al., "The association between antiphospholipid antibodies and related clinical outcomes: a critical review of the literature," Arthritis & Rheumatism, vol. 65, p. S1129, 2013.
10. P. G. De Groot, B. Lutters, R. H. W. M. Derksen, T. Lisman, J. C. M. Meijers, and F. R. Rosendaal, "Lupus anticoagulants and the risk of a first episode of deep venous thrombosis," Journal of Thrombosis and Haemostasis, vol. 3, no. 9, pp. 1993-1997, 2005.
11. A. Ruffatti, T. Del Ross, M. Ciprian et al., "Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study," Annals of the Rheumatic Diseases, vol. 68, no. 3, pp. 397-399, 2009.
12. M. G. Tektonidou, K. Laskari, D. B. Panagiotakos, and H. M. Moutsopoulos, "Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies," Arthritis Care and Research, vol. 61, no. 1, pp. 29-36, 2009.
13. Y. Shoenfeld, M. Blank, R. Cervera, J. Font, E. Raschi, and P.-L. Meroni, "Infectious origin of the antiphospholipid syndrome," Annals of the Rheumatic Diseases, vol. 65, no. 1, pp. 2-6, 2006.
14. G. Ruiz-Irastorza, M. A. Khamashta, B. J. Hunt, A. Escudero, M. J. Cuadrado, and G. R. V. Hughes, "Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5," Archives of Internal Medicine, vol. 162, no. 10, pp. 1164-1169, 2002.
15. S. Krnic-Barrie, C. R. O'Connor, S. W. Looney, S. S. Pierangdi, and E. N. Harris, "A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis," Archives of Internal Medicine, vol. 157, no. 18, pp. 2101-2108, 1997.
16. B. E. Tan, B. Y. H. Thong, S. Shivananda, W. W. Han, and H. H. Chng, "Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort," Lupus, vol. 18, no. 8, pp. 752-758, 2009.
17. C. Neville, J. Rauch, J. Kassis et al., "Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort," Thrombosis and Haemostasis, vol. 101, no. 1, pp. 100-107, 2009.
18. V. Pengo, A. Ruffatti, C. Legnani et al., "Clinical course of high-risk patients diagnosed with antiphospholipid syndrome," Journal of Thrombosis and Haemostasis, vol. 8, no. 2, pp. 237-242, 2010.
19. M. A. Crowther, J. S. Ginsberg, J. Julian et al., "A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome," The New England Journal of Medicine, vol. 349, no. 12, pp. 1133-1138, 2003.
20. G. Finazzi, R. Marchioli, V. Brancaccio et al., "A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)," Journal of Thrombosis and Haemostasis, vol. 3, no. 5, pp. 848-853, 2005.
21. W. Lim, M. A. Crowther, and J. W. Eikelboom, "Management of antiphospholipid antibody syndrome: a systematic review," Journal of the American Medical Association, vol. 295, no. 9, pp. 1050-1057, 2006.
22. G. Ruiz-Irastorza, B. J. Hunt, and M. A. Khamashta, "A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies," Arthritis Care and Research, vol. 57, no. 8, pp. 1487-1495, 2007.
23. G. Ruiz-Irastorza, M. J. Cuadrado, I. Ruiz-Arruza et al., "Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies," Lupus, vol. 20, no. 2, pp. 206-218, 2011.
24. H. Cohen and S. J. MacHin, "Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?" Lupus, vol. 19, no. 4, pp. 486-491, 2010.
25. J. Guerin, Y. Sheng, S. Reddel, G. M. Iverson, M. G. Chapman, and S. A. Krilis, "Heparin inhibits the binding of β2-glycoprotein I to phospholipids and promotes the plasminmediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome," The Journal of Biological Chemistry, vol. 277, no. 4, pp. 2644-2649, 2002.
26. M. Bazzan, A. Vaccarino, S. Stella et al., "Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort," Autoimmunity Reviews, vol. 12, no. 8, pp. 826-831, 2013.
27. P. R. J. Ames, A. Ciampa, M. Margaglione, G. Scenna, L. Iannaccone, and V. Brancaccio, "Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia," Thrombosis and Haemostasis, vol. 93, no. 4, pp. 694-699, 2005.
28. C. Kearon, E. A. Akl, A. J. Comerota et al., "Antithrombotic therapy for wi disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines," Chest, vol. 141, no. 2, supplement, pp. e419S-e494S, 2012.
29. P. Prandoni, P. Simioni, and A. Girolami, "Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation," Thrombosis and Haemostasis, vol. 75, no. 5, article 859, 1996.
30. J. S. Ginsberg, P. S. Wells, P. Brill-Edwards et al., "Antiphospholipid antibodies and venous thromboembolism," Blood, vol. 86, no. 10, pp. 3685-3691, 1995.
31. A. Rance, J. Emmerich, and J.-N. Fiessinger, "Anticardiolipin antibodies and recurrent thromboembolism," Thrombosis and Haemostasis, vol. 77, no. 1, pp. 221-222, 1997.
32. S. Schulman, E. Svenungsson, and S. Granqvist," Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group," American Journal of Medicine, vol. 104, no. 4, pp. 332-338, 1998.
33. M. H. Rosove and P. M. C. Brewer, "Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients," Annals of Internal Medicine, vol. 117, no. 4, pp. 303-308, 1992.
34. M. A. Khamashta, M. J. Cuadrado, F. Mujic, N. A. Taub, B. J. Hunt, and G. R. V. Hughes, "The management of thrombosis in the antiphospholipid-antibody syndrome," The New England Journal of Medicine, vol. 332, no. 15, pp. 993-997, 1995.
35. R. H. W. M. Derksen, P. G. de Groot, L. Kater, and H. K. Nieuwenhuis, "Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment," Annals of the Rheumatic Diseases, vol. 52, no. 9, pp. 689-692, 1993.
36. L. Michaels, "Incidence of thromboembolism after stopping anticoagulant therapy. Relationship to hemorrhage at the time of termination," Journal of the American Medical Association, vol. 215, no. 4, pp. 595-599, 1971.
37. E. Coloma Bazán, C. Donate López, P. Moreno Lozano, R. Cervera, and G. Espinosa, "Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative," Immunologic Research, vol. 56, no. 2-3, pp. 358-361, 2013.
38. J. Criado-García, R. A. Fernández-Puebla, L. López Jiménez, F. Velasco, M. Santamaría, and A. Blanco-Molina, "Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative," Revista Clinica Espanola, vol. 208, no. 3, pp. 135-137, 2008.
39. A. K. Wittkowsky, J. Downing, J. Blackburn, and E. Nutescu, "Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic," Thrombosis and Haemostasis, vol. 96, no. 2, pp. 137-141, 2006.
40. F. J. Muñoz-Rodríguez, J. Font, R. Cervera et al., "Clinical study and follow-up of 100 patients with the antiphospholipid syndrome," Seminars in Arthritis and Rheumatism, vol. 29, no. 3, pp. 182-190, 1999.
41. J. A. Girón-González, E. G. del Río, C. Rodríguez, J. Rodríguez-Martorell, and A. Serrano, "Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals," The Journal of Rheumatology, vol. 31, no. 8, pp. 1560-1567, 2004.
42. S. R. Levine, R. L. Brey, B. C. Tilleyetal.,"Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke," The Journal of the American Medical Association, vol. 291, no. 5, pp. 576-584, 2004.
43. H. Okuma, Y. Kitagawa, T. Yasuda, K. Tokuoka, and S. Takagi, "Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome," International Journal of Medical Sciences, vol. 7, no. 1, pp. 15-18, 2010.
44. Y. Fujieda, O. Amengual, and T. Watanabe, "Dual antiplatelet therapy as prophylaxis of recurrent arterial thrombosis in patients with antiphospholipid syndrome," Arthritis & Rheumatology, vol. 64, supplement 10, p. S1036, 2012.
45. R. L. Bick and J. Rice, "Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety - a preliminary report," Clinical and Applied Thrombosis/Hemostasis, vol. 5, no. 1,supplement, pp. S67-S71, 1999.
46. S. Ahmed, A. Karim, D. Patel, R. Siddiqui, and J. Mattana, "Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome," American Journal of the Medical Sciences, vol. 324, no. 5, pp. 279-280, 2002.
47. F. Dentali, E. Manfredi, M. Crowther, and W. Ageno, "Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy," Journal of Thrombosis and Haemostasis, vol. 3, no. 9, pp. 2121-2123, 2005.
48. J. A. Vargas-Hitos, O. Ateka-Barrutia, S. Sangle, and M. A. Khamashta, "Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome," Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1652-1654, 2011.
49. D. Erkan, J. T. Merrill, Y. Yazici, L. Sammaritano, J. P. Buyon, and M. D. Lockshin, "High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin," Arthritis and Rheumatism, vol. 44, no. 6, pp. 1466-1467, 2001.
50. D. Erkan, Y. Yazici, M. G. Peterson, L. Sammaritano, and M. D. Lockshin, "A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome," Rheumatology, vol. 41, no. 8, pp. 924-929, 2002.
51. Y. M. Mok, E. Y. T. Chan, D. Y. T. Fong, K. F. S. Leung, S. W. Woon, and S. L. Chak, "Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus," Journal of Rheumatology, vol. 32, no. 4, pp. 622-628, 2005.
52. T. Tarr, G. Lakos, H. P. Bhattoa, Y. Shoenfeld, G. Szegedi, and E. Kiss, "Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients," Lupus, vol. 16, no. 1, pp. 39-45, 2007.
53. D. Erkan, M. J. Harrison, R. Levy et al., "Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals," Arthritis and Rheumatism, vol. 56, no. 7, pp. 2382-2391, 2007.
54. M. J. Cuadrado, M. L. Bertolaccini, P. T. Seed et al., "Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)," Rheumatology, vol. 53, no. 2, pp. 275-284, 2014.
55. A. Kužnik, M. Benèina, U. Švajger, M. Jeras, B. Rozman, and R. Jerala, "Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines," Journal of Immunology, vol. 186, no. 8, pp. 4794-4804, 2011.
56. R. G. Espinola, S. S. Pierangeli, A. E. Ghara, and E. N. Harris"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies," Thrombosis and Haemostasis, vol. 87, no. 3, pp. 518-522, 2002.
57. J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes, "Hydroxychloroquine directly reduces the bindin of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers," Blood, vol. 112, no. 5, pp. 1687-1695, 2008.
58. J. H. Rand, X.-X. Wu, A. S. Quinn et al., "Hydroxychloroquine protects the annexinA5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug," Blood, vol. 115, no. 11, pp. 2292-2299, 2010.
59. M. H. Edwards, S. Pierangeli, X. Liu, J. H. Barker, G. Anderson, and E. Nigel Harris, "Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice," Circulation, vol. 96, no. 12, pp. 4380-4384, 1997.
60. A. Schmidt-Tanguy, J. Voswinkel, D. Henrion et al., "Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients," Journal of Thrombosis and Haemostasis, vol. 11, no. 10, pp. 1927-1929, 2013.
61. D. Erkan, C. L. Aguiar, D. Andrade et al., "14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends," Autoimmunity Reviews, vol. 13, no. 6, pp. 685-696, 2014.
62. C. B. Chighizola, M. Moia, and P. L. Meroni, "New oral anticoagulants in thrombotic antiphospholipid syndrome," Lupus, vol. 23, no. 12, pp. 1279-1282, 2014.
63. N. Noel, F. Dutasta, N. Costedoat-Chalumeau et al., "Safety and efficacy of new oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome," Arthritis & Rheumatism, vol. 66, no. 11, article S4, 2014.
64. S. Sciascia and B. Hunt, "Rivaroxaban use in patients with antiphospholipid syndrome patients and previous poor anticoagulation control with vitamin K antagonists," Arthritis & Rheumatology, vol. 66, no. 11, p. S7, 2014.
65. J. K. Schaefer, R. D. McBane, D. F. Black, L. N. Williams, K. G. Moder, and W. E. Wysokinski, "Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients," Thrombosis and Haemostasis, vol. 112, no. 5, pp. 947-950, 2014.
66. G. Medina, A. L. Gutiérrez-Moreno, O. Vera-Lastra, M. A. Saavedra, and L. J. Jara, "Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients," Autoimmunity Reviews, vol. 10, no. 4, pp. 214-217, 2011.
67. D. E. Ferrara, R. Swerlick, K. Casper et al., "Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells," Journal of Thrombosis and Haemostasis, vol. 2, no. 9, pp. 1558-1563, 2004.
68. P. L. Meroni, E. Raschi, C. Testoni et al., "Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype," Arthritis & Rheumatism, vol. 44, no. 12, pp. 2870-2878, 2001.
69. L. A. Martínez-Martínez, M. C. Amigo, A. Orozco et al., "Effect of rosuvastatin on vascular cell adhesion molecule 1 (vcam-1) expression by human endothelial cells exposed to antiphospholipid syndrome serum," Journal of Clinical Rheumatology, vol. 12, article S80, 2006.
70. C. López-Pedrera, P. Ruiz-Limón, M. Á. Aguirre et al., "Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome," Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 675-682, 2011.
71. D. Erkan, R. Willis, V. L. Murthy et al., "A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients," Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 1176-1180, 2014.
72. N. Agmon-Levin, M. Blank, G. Zandman-Goddard et al., "Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression," Annals of the Rheumatic Diseases, vol. 70, no. 1, pp. 145-150, 2011.
73. S. Piantoni, L. Andreoli, F. Allegri, P. L. Meroni, and A. Tincani, "Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease," Reumatismo, vol. 64, no. 5, pp. 307-313, 2012.
74. K. Klack and J. F. D. Carvalho, "High frequency of vitamin D insufficiency in primary antiphospolipid syndrome," Joint Bone Spine, vol. 77, no. 5, pp. 489-490, 2010.
75. J. A. Paupitz, J. F. de Carvalho, V. F. Caparbo, K. Klack, and R. M. R. Pereira, "Primary antiphospholipid syndrome in premenopausal women: low vitamin D, high fat mass and maintained bone mineral mass," Lupus, vol. 19, no. 11, pp. 1302-1306, 2010.
76. L. Andreoli, S. Piantoni, F. Dall'Ara, F. Allegri, P. L. Meroni, and A. Tincani, "Vitamin D and antiphospholipid syndrome," Lupus, vol. 21, no. 7, pp. 736-740, 2012.
77. A. Y. Y. Lee, M. N. Levine, R. I. Baker et al., "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer," The New England Journal of Medicine, vol. 349, no. 2, pp. 146-153, 2003.
78. E. Konova, "Intravenous immunoglobulin therapy in antiphospholipid syndrome," Clinical Reviews in Allergy and Immunology, vol. 29, no. 3, pp. 229-236, 2005.
79. S. S. Pierangeli, R. Espinola, X. Liu, E. Nigel Harris, and J. E. Salmon, "Identification of an Fcã receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype," Arthritis and Rheumatism, vol. 44, no. 4, pp. 876-883, 2001.
80. Y. Sherer, Y. Levy, and Y. Shoenfeld, "Intravenous immunoglobulin therapy of antiphospholipid syndrome," Rheumatology, vol. 39, no. 4, pp. 421-426, 2000.
81. S. Tenti, G. M. Guidelli, F. Bellisai, M. Galeazzi, and A. Fioravanti, "Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy," Clinical & Experimental Rheumatology, vol. 31, no. 6, pp. 877-882, 2013.
82. S. Sciascia, O. Giachino, and D. Roccatello, "Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin," Clinical and Experimental Rheumatology, vol. 30, no. 3, pp. 409-413, 2012.
83. P. Kahn, M. Ramanujam, R. Bethunaickan et al., "Prevention of murine antiphospholipid syndrome by BAFF blockade," Arthritis & Rheumatism, vol. 58, no. 9, pp. 2824-2834, 2008.
84. A. Akkerman, W. Huang, X. Wang et al., "CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice," Autoimmunity, vol. 37, no. 6-7, pp. 445-451, 2004.
85. W. Stohl, F. Hiepe, K. M. Latinis et al., "Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus," Arthritis and Rheumatism, vol. 64, no. 7, pp. 2328-2337, 2012.
86. M. Ramos-Casals, P. Brito-Zerón, S. Muñoz, and M.-J. Soto, "A systematic review of the off-label use of biological therapies in systemic autoimmune diseases," Medicine, vol. 87, no. 6, pp. 345-364, 2008.
87. S. Khattri, G. Zandman-Goddard, and E. Peeva, "B-cell directed therapies in antiphospholipid antibody syndrome - new directions based on murine and human data," Autoimmunity Reviews, vol. 11, no. 10, pp. 717-722, 2012.
88. D. Erkan, J. Vega, G. Ramón, E. Kozora, and M. D. Lockshin,"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome," Arthritis &Rheumatism, vol. 65, no. 2, pp. 464-471, 2013.
89. K. Suzuki, H. Nagasawa, H. Kameda et al., "Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus," Rheumatology, vol. 48, no. 2, pp. 198-199, 2009.
90. S. Bucciarelli, G. Espinosa, R. Cervera et al., "Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients," Arthritis and Rheumatism, vol. 54, no. 8, pp. 2568-2576, 2006.
91. G. J. Pons-Estel, G. E. Salerni, R. M. Serrano et al., "Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature," Autoimmunity Reviews, vol. 10, no. 11, pp. 679-684, 2011.
92. H. Berman, I. Rodríguez-Pintó, R. Cervera et al., "Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab," Autoimmunity Reviews, vol. 12, no. 11, pp. 1085-1090, 2013.
93. K. Ikeda, K. Nagasawa, T. Horiuchi, T. Tsuru, H. Nishizaka, and Y. Niho, "C5a induces tissue factor activity on endothelial cells," Thrombosis and Haemostasis, vol. 77, no. 2, pp. 394-398, 1997.
94. K. Ritis, M. Doumas, D. Mastellos et al., "A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways," Journal of Immunology, vol. 177, no. 7, pp. 4794-4802, 2006.
95. F. Fischetti, P. Durigutto, V. Pellis et al., "Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor," Blood, vol. 106, no. 7, pp. 2340-2346, 2005.
96. J. Schmidtko, S. Peine, Y. El-Housseini, M. Pascual, and P. Meier, "Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab," American Journal of Kidney Diseases, vol. 61, no. 2, pp. 289-299, 2013.
97. B. E. Lonze, A. L. Singer, and R. A. Montgomery, "Eculizumab and renal transplantation in a patient with CAPS," The New England Journal of Medicine, vol. 362, no. 18, pp. 1744-1745, 2010.
98. I. Shapira, D. Andrade, S. L. Allen, and J. E. Salmon, "Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab," Arthritis & Rheumatism, vol. 64, no. 8, pp. 2719-2723, 2012.
99. G. Canaud, N. Kamar, D. Anglicheau et al., "Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes," American Journal of Transplantation, vol. 13, no. 8, pp. 2179-2185, 2013.
100. B. E. Lonze, A. A. Zachary, C. M. Magro et al., "Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation," American Journal of Transplantation, vol. 14, no. 2, pp. 459-465, 2014.
101. F. Morabito, M. Gentile, F. Gay et al., "Insights into defibrotide: an updated review," Expert Opinion on Biological Therapy, vol. 9, no. 6, pp. 763-772, 2009.
102. A. Falanga, A. Vignoli, M. Marchetti, and T. Barbui, "Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells," Leukemia, vol. 17, no. 8, pp. 1636-1642, 2003.
103. R. A. Asherson, R. Cervera, J.-C. Piette et al., "Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients," Medicine, vol. 80, no. 6, pp. 355-377, 2001.
104. A. Burcoglu-O'Ral, D. Erkan, and R. Asherson, "Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator," The Journal of Rheumatology, vol. 29, no. 9, pp. 2006-2011, 2002.
105. M. Gerosa, C. Chighizola, and P. L. Meroni, "Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases)," Internal and Emergency Medicine, vol. 3, no. 3, pp. 201-203, 2008.
106. L. Arnaud, A. Mathian, A. Ruffatti et al., "Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis," Autoimmunity Reviews, vol. 13, no. 3, pp. 281-291, 2014.
107. C. Chighizola, T. Schioppo, F. Ingegnoli, and P. L. Meroni, "Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis," Current Vascular Pharmacology, vol. 10, no. 5, pp. 639-646, 2012.
108. F. Martínez, M. J. Forner, M. Ruano, N. Abdilla, R. Oltra, and M. J. García-Fuster, "Factors related to the risk of thrombosis in patients with lupus and antiphospholipid antibodies," Medicina Clinica, vol. 127, no. 11, pp. 405-408, 2006.
109. N. M. Shah, M. A. Khamashta, T. Atsumi, and G. R. V. Hughes, "Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients," Lupus, vol. 7, no. 1, pp. 3-6, 1998.
110. D. G. Wahl, H. Bounameaux, P. de Moerloose, and F. P. Sarasin, "Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis," Archives of Internal Medicine, vol. 160, no. 13, pp. 2042-2048, 2000.
111. D. J. Wallace, "Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?" Arthritis and Rheumatism, vol. 30, no. 12, pp. 1435-1436, 1987.
112. G. Ruiz-Irastorza, M.-V. Egurbide, J.-I. Pijoan et al., "Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus," Lupus, vol. 15, no. 9, pp. 577-583, 2006.
113. G. Law, L. Magder, H. Fang, and M. Petri, "Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients," Annals of the Rheumatic Diseases, vol. 71,supplement 3, p. 547, 2014.
114. G. Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron, and M. A. Khamashta, "Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review," Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 20-28, 2010.
115. M. V. Ostertag, X. Liu, V. Henderson, and S. S. Pierangeli, "A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice," Lupus, vol. 15, no. 6, pp. 358-365, 2006.
116. Y. M. de la Torre, F. Pregnolato, F. D'Amelio et al., "Antiphospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β2 glycoprotein I phospholipid-binding site. Implications for human fetal loss," Journal of Autoimmunity, vol. 38, no. 2-3, pp. J209-J215, 2012.
117. Y. Ioannou, Z. Romay-Penabad, C. Pericleous et al., "In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept," Journal of Thrombosis and Haemostasis, vol. 7, no. 5, pp. 833-842, 2009.
118. C. Agostinis, P. Durigutto, D. Sblattero et al., "A non-complement-fixing antibody to β2 glycoprotein i as a novel therapy for antiphospholipid syndrome," Blood, vol. 123, no. 22, pp. 3478-3487, 2014.
119. B. Giannakopoulos and S. A. Krilis, "The pathogenesis of the antiphospholipid syndrome," The New England Journal of Medicine, vol. 368, no. 11, pp. 1033-1044, 2013.
120. A. Kolyada, C.-J. Lee, A. de Biasio, and N. Beglova, "A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome," PLoS ONE, vol. 5, no. 12, Article ID e15345, 2010.
121. A. Kolyada, A. Porter, and N. Beglova, "Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome," Blood, vol. 123, no. 7, pp. 1090-1097, 2014.
122. C. Comarmond and P. Cacoub, "Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies," Autoimmunity Reviews, vol. 12, no. 7, pp. 752-757, 2013.
123. M. Nishimura, T. Nii, G. Trimova et al., "The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome," Journal of Nephropathology, vol. 2, no. 2, pp. 114-121, 2013.
124. S. S. Pierangeli and D. Erkan, "Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?" Lupus, vol. 19, no. 4, pp. 475-485, 2010.
125. H. Zhou, A. S. Wolberg, and R. A. S. Roubey, "Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep," Blood, vol. 104, no. 8, pp. 2353-2358, 2004.
126. H. Zhou, "Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome," Acta Pharmacologica Sinica, vol. 25, no. 10, pp. 1366-1371, 2004.
127. T. Scoble, S. Wijetilleka, and M. A. Khamashta, "Managementof refractory anti-phospholipid syndrome," Autoimmunity Reviews, vol. 10, no. 11, pp. 669-673, 2011.
128. R. Jasuja, F. H. Passam, D. R. Kennedy et al., "Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents," Journal of Clinical Investigation, vol. 122, no. 6, pp. 2104-2113, 2012.
129. C. Perez-Sanchez, P. Ruiz-Limon, M. A. Aguirre et al., "Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment," Blood, vol. 119, no. 24, pp. 5859-5870, 2012.